Their ad budgets are shifting from linear TV to digital channels like CTV and social media, but big TV events still garner significant spending.

Novo drops court fights to secure GLP-1 distribution, which will drive other telehealth brands to weigh pharma deals against legal risk.

It rolled out a direct-to-employer payment model aimed at expanding weight loss drug access at work with flat pricing.

Hims & Hers’ former partner plans to continue copycat GLP-1 sales even as FDA investigations and patent lawsuits raise the risks.

Data shows the first decline in obesity rates in US adults, but children and teens moved in the opposite direction.

Drugmakers’ price drops don’t affect all patients the same. Brands and marketers must decode cost complexities where patients already seek out weight loss advice, like on social media.

Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.

Novo’s drug candidate CagriSema lagged Lilly’s Zepbound in weight loss trials, sending Novo shares down 15% and widening Lilly’s market lead.

India’s GLP-1 rollout next month signals tougher pricing ahead for GLP-1 brands.

Its recent Pfizer and TrumpRx partnerships show how pharma companies are betting on D2C distribution and consumer-facing pricing.

Novo’s lawsuit and regulator warnings signal a crackdown on compounded GLP-1s across telehealth.

Big linear TV won’t wow all viewers, but the massive reach can still drive research, provider talks, and care.

Novo’s Big Game spot can help reinforce the Wegovy pill’s credibility against copycat compounded versions.

Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.

Weight loss hype pushed Lilly well ahead of Novo, yet Novo’s early pill win signals a turn toward more affordable, convenient obesity treatments.

But a crowded obesity market demands product differentiation, fewer side effects, and benefits beyond weight loss to reap financial gains.

Pharma and health brands return to the Super Bowl, ditching drug pitches for brand storytelling campaigns.

Novo’s oral drug is wildly outperforming weekly sales needed to hit forecasts, signaling strong early demand for GLP-1 pills.

Roche’s obesity drug results show up to 22.5% weight loss, hinting at future competition for Novo and Lilly.

Lilly’s tirzepatide is projected to top 2026 sales as pills and uses beyond diabetes and weight loss expand demand.